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Type of vascular access and mortality in U.S. hemodialysis ysis Outcomes Quality Initiative (DOQI) recommend ar-
patients. teriovenous fistula (AVF) to be the VA of choice for he-
Background. Vascular access (VA) complications account for modialysis [3]. These guidelines are based on studies that16 to 25% of hospital admissions. This study tested the hypothe-
suggest improved access survival and function for AVFsis that the type of VA in use is correlated with overall mortality
and cause-specific mortality. when compared with arteriovenous graft (AVG) [4–8].
Methods. Data were analyzed from the U.S. Renal Data A substantial geographic variation exists in the distribu-
System Dialysis Morbidity and Mortality Study Wave 1, a ran- tion of AVF and AVG among patients with end-stagedom sample of 5507 patients, prevalent on hemodialysis as of
renal disease (ESRD). While in Europe 81% of VA areDecember 31, 1993. The relative mortality risk during a two-
AVF, the percentage of hemodialysis patients with AVFyear observation was analyzed by Cox-regression methods with
adjustments for demographic and comorbid conditions. Using in the United States is only 21% (abstract; Pisoni, J Am
similar methods, cause-specific analyses also were performed for Soc Nephrol 10:215A, 1999). Even within the United States,death caused by infection and cardiac causes.
there is a considerable geographic variation in placementResults. In diabetic mellitus (DM) patients with end-stage
of AVF. Hirth et al showed a tenfold regional variation,renal disease, the associated relative mortality risk was higher
for those with arteriovenous graft (AVG; RR  1.41, P  with the East South Central region of the United States
0.003) and central venous catheter (CVC; RR  1.54, P  having a 2.7-fold higher adjusted odds ratio for place-0.002) as compared with arteriovenous fistula (AVF). In non-
ment of AVG than the national average, whereas thisDM patients, those with CVC had a higher associated mortality
ratio was only 0.2 for the New England region [9]. This(RR  1.70, P  0.001), as did to a lesser degree those with
AVG (RR 1.08, P 0.35) when compared with AVF. Cause- large variation is not likely due to differences in patient
specific analyses found higher infection-related deaths for CVC characteristics, but rather to variation in practice pat-(RR  2.30, P  0.06) and AVG (RR  2.47, P  0.02)
terns across the United States [10].compared with AVF in DM; in non-DM, risk was higher also
Despite recent trends in improved survival of hemodi-for CVC (RR  1.83, P  0.04) and AVG (RR  1.27, P 
0.33). In contrast to our hypothesis that AV shunting increases alysis patients, mortality rates are 22.8 deaths per 100 pa-
cardiac risk, deaths caused by cardiac causes were higher in tient years during the first year on hemodialysis. The five-
CVC than AVF for both DM (RR  1.47, P  0.05) and non-
year survival for the average patient on hemodialysis isDM (RR  1.34, P  0.05) patients.
merely 25 to 27% [11]. Cardiac diseases account for moreConclusion. This case-mix adjusted analysis suggests that CVC
and AVG are correlated with increased mortality risk when com- than half of the reported causes of deaths, while deaths
pared with AVF, both overall and by major causes of death. due to infection make up almost a quarter of all deaths.
The risk of infection among hemodialysis patients is rela-
tively high due to the presence of a VA and the repeatedVascular access (VA) complications account for 16 to
need to access the bloodstream for hemodialysis. A Ca-25% of hospital admissions and cost over $1 billion U.S.
nadian study showed that the probability of access infec-dollars annually [1, 2]. Guidelines from the current Dial-
tion was higher for AVG than for AVF (19.7 vs. 4.5%)
during a 12-month observation period [12]. It is com-
Key words: dialysis, central venous catheter, arteriovenous graft, mor-
monly thought that the probability of infection with atality, arteriovenous fistula, USRDS study, cardiac death, end-stage
renal disease, diabetes mellitus. central venous catheter (CVC) is even higher. Access
thrombosis rates were higher also for AVG in this Cana-Received for publication December 28, 2000
dian study, with a 2.5 times higher relative risk for AVGand in revised form March 28, 2001
Accepted for publication April 27, 2001 when compared with AVF. Additionally, those with
AVG had a 50% higher relative risk for hospitalization 2001 by the International Society of Nephrology
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when compared with AVF [12]. Recently, Woods et al ber 31, 1993), had a functioning kidney transplant, were
in training for any self-care treatment, or were receivinganalyzed Medicare data and found that the risk of access
peritoneal dialysis or home hemodialysis at the studyfailure was 67% higher for AVG than for AVF. Their
start date [18].analysis also showed an increase in the rate of AVF
A copy of the data abstraction form and further designthrombosis with age. However, even for patients older
details of the DMMS Wave 1 have been published inthan 65 years, AVG had a 24% higher relative risk of
the USRDS 1999 Annual Data Report, Appendix B [18].failure when compared with AVF [13]. Thus, both higher
Standardized forms were sent to each dialysis unit, whererates of thrombosis and infection were associated with
personnel abstracted data on demographics, comorbidthe use of AVG. The overall risk of infection may be
conditions, laboratory, treatment, socioeconomic, andreduced with utilization of an AVF at initiation of hemo-
insurance status. Details abstracted for each patient in-dialysis. Furthermore, it has been estimated that for each
cluded date of birth, gender, race, education level, mobil-0.1 unit decrease in Kt/V, the mortality rate increases
ity status, cause of ESRD, and a list of comorbid condi-by 7%, all else being equal. Mean delivered dialysis dose
tions present within 10 years prior to study start datein turn varies by type of access, with a CVC providing
(December 31, 1993). This form included specific ques-0.1 lower Kt/V than AVG or AVF [10, 13, 14]. Since
tions regarding coronary artery disease (CAD), conges-dialysis dose, infection, and hospitalization are associ-
tive heart failure (CHF), pericarditis, cerebrovascularated with mortality risk, we hypothesized that VA is
disease, peripheral vascular disease (PVD), diabetes, in-correlated with patient survival.
sulin use, lung disease, cancer, and HIV status. Data alsoTo date, limited data have been published regarding
were abstracted regarding VA in use on December 31,patient survival and its association with type of VA in he-
1993 for all patients. For a subsample of incident pa-modialysis patients [15–17]. In the present study, we used
tients during 1993, a special form was used to collectdata from the United States Renal Data System (USRDS)
data regarding VA. For this subset, data were collectedDialysis Morbidity and Mortality Study (DMMS) Wave 1
regarding VA used at the initiation of hemodialysis andto correlate mortality rates with types of VA while statis-
at 30 days post-initiation of dialysis. For our study, thetically adjusting for patient characteristics and comorbid
AVG group included those with polytetrafluoroethyleneconditions. We hypothesized that patients with CVC have
(PTFE) (98%) and bovine graft (2%), and the CVCthe highest associated mortality risk, followed by those
group included those with permanent catheters (39%)with AVG, and that patients with AVF have the lowest
and temporary catheters (61%). Date and cause of deathassociated mortality risk. This study also analyzed the
were obtained from the USRDS standard analysis files.data on cause of death by VA type. Our hypothesis was
that, compared with patients with CVC, those with AVF Prevalent patient analyses
or AVG have higher associated risk of death from car- These analyses compared survival for all hemodialysis
diac causes because of the increased cardiac output sec- patients by the three VA groups of AVF, AVG, and CVC,
ondary to presence of an AV shunt. We anticipated that after adjusting the final model for age, gender, race, body
associated death risk due to infection would be highest mass index (BMI), history of smoking, CAD, PVD, cere-
in those with CVC, followed by AVG, and would be brovascular disease, CHF, cancer, ability to ambulate, and
lowest for AVF. education level. Prior knowledge based on literature and
baseline characteristics of our study guided the decision
to choose these variables for inclusion in the final modelMETHODS
[10]. The possibility of interactions between diabetes andData collection
type of VA was explored, as well as between age and VA
Data for this study came from the USRDS DMMS type, and between time on dialysis and VA type on out-
Wave 1. This is an observational study in which demo- comes. The chi-square and analysis of variance tests in
graphic, comorbid, laboratory, treatment, socioeconomic, the SAS program (SAS version 6.12; Cary, NC, USA)
and insurance data were collected on a large representa- were used for categorical and continuous variables,
tive sample of hemodialysis patients in the United States. respectively, to test whether there were differences in
The sample was created by randomly selecting 550 dial- baseline characteristics among the three groups. Survival
ysis units from the Master List of Medicare Approved probabilities were obtained using the Cox (proportional
Dialysis Facilities. Sampling was adjusted to provide an hazard) regression method with the command PROC
adequate sample of new ESRD patients on hemodialysis PHREG in the SAS program. We tested the proportional
(25% of total sampled population). From the 550 se- hazards assumption by testing Log(log) survival.
lected facilities, core data were collected on a total of
“Incident” patient analyses5507 in-center hemodialysis patients who were alive on
December 31, 1993. Patients were excluded if they were Incident patients were defined as the subgroup of prev-
alent patients who initiated chronic dialysis between Oc-less than 15 years of age at the study start date (Decem-
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Table 1. Baseline characteristics
Prevalent patient sample Incident subgroup
All AVF AVG CVC All
Characteristic N5344 N1340 N3129 N875 P value N1101
100 25 59 16 100
Mean age years 59.2 56.2 60.3 59.6 0.0001 60.8
Body mass index kg/m2 24.8 24.1 25.2 24.3 0.0001 25.1
Race, % 0.0001
White 50.9 54.7 46.7 60.6 59.8
Black 40.5 34.5 44.8 33.7 32.3
Other 8.6 10.8 8.5 5.7 7.9
Gender %
Female 49.3 33.4 55.6 51 0.0001 47.7
Cause of ESRD %
Diabetes 31.5 26.7 32.7 34.4 0.0001 36.3
Hypertension 29 26.9 30.4 26.9 0.02 29.2
Glomerulonephritis 12.9 17.7 11.2 11.9 0.0001 11.6
Other 20.8 23.4 19.9 20.1 0.03 15.5
High school graduate % 48.5 54.1 45.6 50.1 0.0001 48.6
Married % 47.2 52.7 45.4 45.1 0.0001 51.1
Abbreviations are: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter; ESRD, end-stage renal disease.
tober 2, 1993, and December 31,1993. In this subset of on 5344 patients. Follow-up survival data were available
on 5198 (97%) patients. These patients were divided bypatients, the study start date was 90 days after the day
of dialysis initiation; thus, patients dying before day 90 cause of ESRD into nondiabetic (N 3570) and diabetic
(N 1628) groups because subsequent analysis revealedwere excluded from the analysis. Access in use at 30 days
was considered to be the access at start of study. For significant outcome differences by VA for these groups.
In the two-year follow-up period, there were a total ofsurvival analyses, the Cox regression method was em-
ployed in the same fashion as described previously in 1678 deaths. Of these, 762 deaths (45% of total) were
due to cardiac causes, and 192 deaths (11% of total)this article.
were due to infection.
Cause of death analyses The baseline characteristics of patients for both overall
and by type of VA, and for the subgroup of incidentIn addition, cause of death analyses were performed
by type of VA for the prevalent patients. Cause of death samples are shown in Table 1. Patients with AVF tended
to be younger in both the prevalent and incident (datawas ascertained from the ESRD Death Notification form.
We defined deaths caused by cardiac causes as those with not shown) patients when compared with CVC or AVG.
Compared with all prevalent patients, those with AVGprimary cause of death due to acute myocardial infarc-
were more likely black and tended to have a higher BMI.tion, pericarditis, athersclerotic heart disease, cardiomy-
Female and diabetic patients were significantly underopathy, cardiac arrhythmia, cardiac arrest, and valvular
represented in the group with AVF when compared withheart disease. In a sensitivity analysis, patients with a
the overall study population. Those with AVF were sig-primary cause of death such as “cardiac arrest, cause un-
nificantly more likely to have graduated from high schoolknown” were not included in the group of patients with
and be married.death due to cardiac causes. Death due to infections was
Table 2 reveals the distribution of comorbid conditionsdefined as those listing as primary cause of death due to
and selected laboratory parameters for prevalent andsepticemia (secondary to VA or PVD or other), pulmo-
incident patients and for the types of VA. In prevalentnary infection (due to bacterial or other causes), and
patients, those with AVF were less likely to have historyother infections (except tuberculosis and viral and fungal
of diabetes, PVD, CAD, CHF, and cancer. In those withinfections). Cox regression was performed to test whe-
available laboratory data, serum albumin, hematocrit,ther AVF, AVG, or CVC was an independent predictor
calcium, phosphate, and creatinine values tended to beof death due to infectious or cardiac causes. Patients
higher in those with AVF. Dialysis dose calculated fromdying of causes other than the cause of interest were
pre- and post-blood urea nitrogen (BUN) levels andcensored at death.
weight as single-pool Kt/V was approximately 10% lower
for prevalent patients with CVC than those with AVF
RESULTS or AVG.
There were 5507 prevalent patients in DMMS WAVE 1. Figures 1 and 2 show the two-year adjusted survival
curves for patients with diabetic and nondiabetic causesOf these patients, VA and comorbid data were available
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Table 2. Distribution of various comorbid conditions and laboratory parameters
Prevalent patients (N5344) Incident subgroup (N1090)
All AVF AVG CVC P value All
Ambulatory % 85.7 90.8 84.6 81.7 0.0001 87
Smoker % 40.7 40.1 40.5 42.3 0.55 42.5
Coronary disease % 44.5 37 46.6 48.3 0.0001 48.6
Congestive heart failure % 43 38.8 43.9 46.5 0.0006 44.3
Peripheral vascular disease % 28.1 22.4 29.8 30.6 0.001 26.9
Cancer % 9.8 8.1 10.1 11.4 0.02 10.7
Pulmonary disease % 12.2 11.3 12.1 13.8 0.19 13.1
History of diabetes % 43.6 33.7 46.9 47 0.0001 50.1
Insulin requiring diabetes % 31.4 24.3 33.6 34.1 0.0001 35.4
Laboratory parameters
Creatinine mg/dL 10.2 11.3 10.2 8.7 0.0001 8.8
Cholesterol mg/dL 176 170 178 181 0.0001 187
Hematocrit % 30.1 31 30.2 28.6 0.0001 3.4
Albumin g/dL 3.7 3.8 3.7 3.5 0.0001 3.4
Calcium mg/dL 9.2 9.3 9.2 8.8 0.0001 8.5
Phosphate mg/dL 5.9 6.1 5.9 5.7 0.0001 5.4
Kt/V (single pool) 1.19 1.18 1.22 1.08 0.0001 1.03
Abbreviations are: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter.
Fig. 1. Adjusted patient survival (Cox)* for various vascular access Fig. 2. Adjusted patient survival (Cox)* for various VA types in preva-
(VA) types [arteriovenous fistula (AVF); arteriovenous graft (AVG); lent nondiabetic patients. *Adjusted for the average diabetic patient
central venous catheter (CVG)] in prevalent diabetic patients. *Ad- overall (Cox). Covariates in the model included age, race, gender, BMI,
justed for the average diabetic patient overall (Cox). Covariates in the history of smoking, PVD, CAD, CHF, neoplasm, ability to ambulate,
model included age, race, gender, body mass index (BMI), history of and education level.
smoking, peripheral vascular disease (PVD), coronary artery disease
(CAD), chronic heart failure (CHF), neoplasm, ability to ambulate,
and education level.
patients and incident patients for diabetic adjusting for
the same comorbid factors as for Figure 1. Similarly,
Figure 4 shows the relative risk of death for nondiabeticof ESRD by three VA categories. These curves were ad-
patients. Separate models were used for diabetics andjusted for age, race, gender, BMI, smoking, education
nondiabetics because of a significant interaction betweenlevel, ability to ambulate, and history of PVD, CAD,
diabetic status and type of VA (P  0.05). The interac-CHF, and cancer. For both diabetics and nondiabetics,
tion between age and VA type and time on dialysis andthose with AVF had a better overall patient survival
VA type also was tested but was not significant. In preva-compared with those with AVG. The group with CVC
lent diabetic patients, AVG was associated with a 41%clearly had a worse survival rate. In nondiabetics, the
higher risk of death (RR  1.41, 95% CI, 1.13 to 1.77)difference in adjusted survival was apparent as early as
than AVF. Similarly, for those with CVC the relativetwo months after the start of the study. The relative
mortality risk was 54% higher (RR 1.54, 95% CI, 1.17difference persisted through the two years of follow-up.
Figure 3 shows the relative risk of death in prevalent to 2.02) than those with AVF. In prevalent nondiabetic
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Fig. 4. Adjusted* relative risk of death by VA types among nondiabeticFig. 3. Adjusted* relative risk of death by VA types among diabetic pa-
patients. *Adjusted for age, race, gender, BMI, history of smoking, PVD,tients. *Adjusted for age, race, gender, BMI, history of smoking, PVD,
CAD, CHF, neoplasm, ability to ambulate and education level. Preva-CAD, CHF, neoplasm, ability to ambulate and education level. Preva-
lent nondiabetic patients: CVC vs. AVG (P 0.0001). Incident nondia-lent diabetic patients: CVC vs. AVG (P  0.42). Incident diabetic
betic patients: CVC vs. AVG (P  0.82).patients: CVC vs. AVG (P  0.48).
95% CI, 0.73 to 1.16) when compared with the AVFpatients, those with AVG had marginally (8%) higher
group. We also performed a sensitivity analysis in whichbut statistically not significant relative risk (RR  1.08,
those with the cause of death listed as “cardiac arrest,95% CI, 0.92 to 1.26) of death, and those with CVC had
cause unknown” were excluded from the category ofa 70% higher relative risk of death (RR  1.70, 95%
death due to cardiac causes. The results of this analysisCI, 1.41 to 2.05) when compared with those with AVF.
were similar to the previous analysis.Figures 3 and 4 also show the corresponding results for
To test whether older patients or those with a priorthe subset of incident patients.
history of CHF who also had a shunt (AVF or AVG),Among the incident diabetic patients, a similar pattern
and as a result higher cardiac output, might be at a higherwas seen, although the differences did not reach statisti-
associated risk for death from cardiac causes, separatecal significance. Those with AVG had a substantially
analyses were done. However, patients with a previoushigher associated risk of death at 64% (RR  1.64, 95%
history of CHF and with CVC as their VA had higherCI, 0.84 to 3.22) and those with CVC had a 91% higher
relative risk of death due to cardiac causes when com-(RR  1.91, 95% CI, 0.98 to 3.72) risk of death when
pared with those with AVF and AVG. Although the re-compared with the AVF group. In incident nondiabetic
sults for these smaller subgroups were not statisticallypatients, those with AVG had a 12% higher associated
significant, both the direction and the average effect sizerisk of death (RR  1.12, 95% CI, 0.69 to 1.82), and
were similar to overall prevalent group. Similarly, inthose with CVC had a 16% higher (RR  1.16, 95% CI,
patients over the age of 65, there was no consistent pat-0.72 to 1.87) risk of death than those with AVF. In a
tern to suggest that a high cardiac output was associatedseparate model of incident patients with available data
with higher death due to cardiac causes.on baseline hematocrit and albumin, we added these
Figure 6 summarizes the results for the cause of deathcovariates to our final model of incident patients. In
due to infection analyses of prevalent diabetic and nondi-diabetics, the associated relative risk of mortality in those
abetic patients. In diabetics, the associated risk of deathwith CVC was 1.64 (95% CI, 0.75 to 3.60) and in those
due to infection was 2.47 (95% CI, 1.16 to 5.25) timeswith AVG was 1.65 (95% CI, 0.75 to 3.63). The associ-
higher for AVG and 2.30 times higher for CVC (95% CI,ated relative risk of mortality in nondiabetic patients
0.96 to 5.52) when compared with AVF. In nondiabetics,with AVG and CVC was 1.18 (95% CI, 0.70 to 2.00)
AVG was associated with 27% higher (RR  1.27, 95%and 1.01 (95% CI, 0.59 to 1.71), respectively. These re-
CI, 0.78 to 2.06) and CVC with 83% higher (RR  1.83,sults are consistent with our final reported model.
95% CI, 1.03 to 3.28) risk of death due to infectionsFigure 5 shows an increased associated risk of death
when compared with those with AVF. Thus, patientsdue to cardiac cause in diabetics associated with AVG
with CVC and AVG were associated with a higher riskand CVC (RR  1.35, 95% CI, 0.98 to 1.85 and RR 
of death due to infection compared with those with AVF1.47, 95% CI, 1.0 to 2.16, respectively) versus AVF. In
in both diabetics and nondiabetics.nondiabetics, the relative risk of death due to cardiac
causes was higher in the CVC group (RR  1.38, 95% In a separate analysis, those with a CVC were further
subdivided into tunneled and temporary catheter sec-CI, 1.01 to 1.77) but not in those with AVG (RR  0.92,
Dhingra et al: Access type predicts mortality1448
Fig. 5. Adjusted* relative risk of death due to cardiac causes by VA type Fig. 6. Adjusted* relative risk of death due to infection by VA type and
and diabetes status. *Adjusted for age, race, gender, BMI, history of smok- diabetes status. *Adjusted for age, race, gender, BMI, history of smok-
ing, PVD, CAD, CHF, neoplasm, ability to ambulate and education ing, PVD, CAD, CHF, neoplasm, ability to ambulate and education
level. Prevalent diabetic patients: CVC vs. AVG (P  0.59). Prevalent level. Prevalent diabetic patients: CVC vs. AVG (P  0.81). Prevalent
nondiabetic patients: CVC vs. AVG (P  0.003). nondiabetic patients: CVC vs. AVG (P  0.13).
tions. In prevalent patients, there were 875 (16% of total) as compared with AVF. To our knowledge, this is the first
patients with CVC, and these were further classified into study to use data collected on a nationally representa-
533 (61%) temporary and 342 (39%) tunneled catheters. tive sample of patients and to focus on the association
The associated relative risk of mortality in prevalent of mortality and cause-specific mortality with various
diabetic patients with a tunneled catheter was 1.79 (95% VA types.
CI, 1.28 to 2.50), and those with a temporary catheter Vascular access complications as morbidity for hemo-
had a relative risk of 1.37 (95% CI, 0.99 to 1.90) when dialysis have received increased attention in recent years
compared with those with AVF. In prevalent nondiabet- [19, 20]. However, there is little evidence of a subsequent
ics, the associated relative risk of mortality in those with time trend toward an increased use of AVF as the pri-
tunneled catheter was 1.88 (95% CI, 1.49 to 2.38), and mary VA. Of the patients in our study who started hemo-
dialysis during the last three months of 1993, only 15%those with temporary catheter had a relative risk of 1.58
had AVF, whereas AVG and CVC accounted for 42 and(95% CI, 1.27 to 1.96) when compared with those with
43% each as their VA in use at 30 days after initiatingAVF. In incident patients, there were 473 (43% of total)
hemodialysis. Among prevalent patients, 23% had AVF;patients with CVC, and these were further subdivided
60% had AVG, and 16% had CVC. Data from the Cen-into 349 (74%) temporary and 124 (26%) tunneled cathe-
ters for Disease Control from December 1999 showedters. The associated relative risk of mortality in incident
a slight difference than in 1993 for prevalent patients,diabetic patients with a tunneled catheter was 2.55 (95%
with 26% having AVF, 52% AVG, and 22% CVC [21].CI, 1.14 to 5.74) and in those with a temporary catheter
Therefore, among the prevalent patients in 1999 the per-RR 1.78 (95% CI, 0.89 to 3.55). In the incident diabet-
centages of patients with AVF had increased; however,ics, the associated relative risk of mortality with a tun-
a simultaneous increase for CVC was even greater. Itneled catheter was 1.37 (95% CI, 0.76 to 2.47) and in
is not clear whether these recent trends will affect thethose with temporary catheter, the relative risk was 1.12
observed relative risks.(95% CI, 0.68 to 1.84).
This study focused on determining whether and to
what degree a particular type of VA is associated with
DISCUSSION the outcome of death. Limited literature has been pub-
This study demonstrates that patients with AVG and lished in this regard previously. Our results suggest that
CVC have a higher overall relative risk of death when the relative risk of death is significantly higher in those
compared with those with AVF, even after adjusting with CVC and AVG when compared with AVF, in both
for various comorbid conditions. Furthermore, the study diabetics and nondiabetics, although the difference in
shows that in diabetics the relative risk of death due to mortality risk was not statistically significant for AVF
infections and cardiac causes was higher in those with versus AVG in the nondiabetics. An earlier study com-
AVG and CVC. The relative risk of death due to infec- pared patient mortality between those with AVG and
AVF and found the 60th percentile of survival of 698tions was also higher in nondiabetics with AVG and CVC
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days for AVF and 771 days for AVG among diabetics, A number of limitations to this current study need to
be considered. Since the design of the study is observa-whereas for nondiabetics, the 60th percentile was at 838
days for AVF and 754 days for AVG [22]. This prior tional, it is susceptible to selection bias. We minimized
this bias by statistically adjusting for several comorbidreport was based on the USRDS Case Mix Adequacy
study and had several limitations. Although it used all conditions that may influence the choice of access type.
These adjustments covered a broad spectrum (Tables 1patients who started dialysis in 1990, it only included
those who were alive on December 31, 1990. Further- and 2). Even with these multiple adjustments, we found
a statistically significant association between the typemore, the analysis was limited to one age group of 65
to 79 years and did not adjust for comorbid conditions of VA and patient mortality. However, the possibility
cannot be excluded that other relevant factors were notexcept for age and diabetes status. To minimize potential
bias due to early deaths, our substudy of incident patients accounted for in this study. It has previously been shown
for incident patients that the type of VA may be relatedonly included patients who started dialysis in the last
three months of 1993 and started the survival analysis to patient acuity or pre-ESRD care [23]. Thus, it is possi-
ble that poor pre-ESRD may have contributed to excesson day 90 for each patient. This resulted in a smaller sam-
ple size and decreased power to detect mortality dif- mortality in those with AVG and CVC. In some preva-
lent patients CVC may be an indicator of previous accessferences. However, the direction and magnitude of the
findings for this subgroup were consistent with results failure, but whether that itself contributes to mortality
is unknown.obtained from the analysis of all prevalent patients hav-
ing a much larger sample size. Because of these major In a different study, we recently reported the associa-
tion between VA type and standardized mortality ratiomethodological differences, direct comparison between
the results from the earlier and the present USRDS study (SMR) at the dialysis unit level (abstract; Wolfe et al,
J Am Soc Nephrol 11:201A, 2000). This analysis mini-is probably not warranted.
Pastan et al presented similar results for prevalent mized comorbid differences between patients, since the
analysis was at the unit level and adjusted for differenceshemodialysis (N  7497) patients from facilities in the
southeastern United States (abstract; Pastan et al, J Am in comorbid conditions at the unit level. The units with
more patients using CVC had 4% higher SMR per 10%Soc Nephrol 11:193A, 2000). However, they did not per-
form separate analyses for diabetic and nondiabetic pa- more patients using CVC when adjusting for demo-
graphic and comorbid conditions at the unit level. Thistients. Their results were similar after adjusting for comor-
bid factors: Temporary and tunneled catheters had nearly analysis suggested that the unit-level practice pattern for
VA is strongly associated with SMR and is consistenttwice the odds of death. AVG had a 20% higher odds of
death overall when compared with patients with AVF. with the patient level results reported in this article.
We considered adding albumin level and dose of dial-Hilbelink et al recently reported their single-center
experience of the impact of hemodialysis access on the sur- ysis to the final model; however, since these factors are
intermediate outcomes that are associated with both VAvival of older patients with ESRD (abstract; J Am Soc
Nephrol 11:185A, 2000). They followed 213 patients (all types and patient mortality, such adjustments may not
be appropriate. In support of this, Leavey et al foundage69) for an average of 26 months and reported worse
patient survival with AVG (23%) followed by AVF (33%) that albumin concentration was significantly correlated
with VA type [24]. In a cross-sectional analysis, albuminand tunneled catheters (52%). These results are very
different from the present study. They performed multi- levels vary as follows: AVF  AVG  tunneled perma-
cath  temporary catheter. They also found that by ad-variate logistic regression for their survival analysis and
did not account for possible differences in various comor- justing for baseline differences, the trend effect predicted
a further decrease in serum albumin at one year forbid conditions. Logistic regression treats early and late
deaths during follow-up as equivalent events, which is a AVG and permanent catheter versus AVF. It also has
been noted that the average blood flows during dialysispotential concern. Our study has several advantages: use
of time-to-death analysis with the Cox regression model, are lower with CVC than with AVG or AVF [25]. Addi-
tionally, increased clotting and infection for AVG com-adjustment for various comorbid conditions, a large sam-
ple size of prevalent hemodialysis patients, and a repre- pared with AVF may lead to a decreased dialysis dose
during the period of access malfunction. Another reasonsentative national sample. In an attempt to replicate the
Hilbelink results, we also performed a separate analysis for not including dialysis dose in this study is that residual
renal function makes it a poor indicator of total Kt/V inof patients with tunneled catheter and compared their
mortality risk with those with AVF and AVG. No evidence incident patients, as they often have substantial residual
renal function. In a separate analysis, the addition of Kt/Vwas found to suggest that tunneled catheters are associ-
ated with a survival advantage; in fact, the results were to the model of mortality in prevalent patients did not
change the results (data not shown). Similarly, the addi-consistent with the overall results reported here for tun-
neled catheter and temporary catheters combined. tion of baseline albumin and hematocrit level measure-
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ments to the model of mortality in incident patients did tors not included in the model may explain for this ele-
vated relative risk of cardiac death in patients with CVC.not change the results. However, we chose not to include
these two factors in our final model for the reasons men- In conclusion, we have shown that the type of VA is
significantly associated with patient mortality. Those withtioned in this paragraph.
Misclassification bias is another potential concern. We CVC and AVG have higher relative risk of mortality
compared with those with AVF. Furthermore, our spe-minimized this bias in the incident group by using the
access in use at 30-days postinitiation of chronic hemodi- cific cause-of-death analyses showed that those with
CVC are at higher risk for death due to infections andalysis. Previously it was shown that a majority of patients
had a permanent access placed at this time. Moreover, cardiac causes. This is the first national study to show
such an association while simultaneously adjusting forthose with CVC may, after switching to AVG or AVF,
have a lower mortality risk. Thus, misclassification would various comorbid factors. These findings suggest that the
type of VA employed may have subsequent implicationsbias results toward the null, resulting in not observing
any differences. The statistically significant observation for survival probability. Since this is the first observation
study to show such an effect on mortality, the resultsand the average effect size seen in this study of access
type on mortality therefore may be an underestimate of need to be confirmed by other observational studies. We
caution that a direct causal link between type of VAthe true differences. The same applies to those with AVG
or AVF when switching to CVC, since they may be mov- and mortality cannot be established based on this study.
However, it is unlikely that a randomized controlled trialing to a higher risk mortality and again lead to an under-
estimate of the effect size. Furthermore, among those of AVF versus AVG will ever be performed. Therefore,
given the large evidence available on a lower morbiditywith CVC, patients with temporary catheters were ob-
served to have a lower risk of mortality than those with with AVF, this study showing a strong and significant
association of AVF with improved patient survival pro-tunneled catheters. This observation could be due also to
misclassification bias. Additionally, the possibility exists vides an additional reason for aggressive pursuit of AVF,
perhaps even beyond the goals of the current DOQIthat other variables or severity indicators not included
in the model may contribute to this observation. guidelines.
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deaths due to infections (abstract; J Am Soc Nephrol 11:
Abbreviations used in this article are: AVF, arteriovenous fistula;193A, 2000). They showed an elevated risk of infection AVG, arteriovenous graft; BMI, body mass index; CAD, coronary ar-
deaths in patients with an AVG, tunneled catheter and tery disease; CHF, congestive heart failure; CI, confidence interval;
CVC, central venous catheter; DM, diabetes mellitus; DMMS, Dialysistemporary catheter compared with AVF (OR 1.5, 4.0,
Morbidity and Mortality Study; DOQI, Dialysis Outcomes Qualityand 2.7, respectively). Initiative; ESRD, end-stage renal disease; Kt/V, dialysis dose; PTFE,
Similar to USRDS reports, we found that death due polytetrafluoroethylene; PVD, peripheral vascular disease; RR, rela-
tive risk; U.S., United States; USRDS, United States Renal Data Sys-to cardiac deaths accounted for 45% of total deaths dur-
tem; VA, vascular access.ing the two-year follow-up period [26]. The study shows
that the associated risk of death due to cardiac cause
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